~~<i id='B241B4696C'><strike id='B241B4696C'><tt id='B241B4696C'><pre id='B241B4696C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

explore

author：hotspot 2025-09-03 03:44:47 - browse：453

A sign of AdventHealth on its building in Orlando, Florida — coverage from STAT — Adobe

A lawsuit between a large hospital system and a dominant vendor that works for health insurance companies is getting a lot more heated — with one party calling the other an “economic parasite.”

The suit, between nonprofit hospital giant AdventHealth and MultiPlan, is now even attracting rare interest from the nation’s biggest hospital lobbyists.

The new, highly detailed legal filings also come right as MultiPlan and more than a dozen of the largest tax-exempt, nonprofit hospital systems are wooing investors at the J.P. Morgan Healthcare Conference. AdventHealth did not attend this year’s conference, but did so last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： CRISPR pioneers react to Casgevy, first gene

explore

focus

explore

hotspot

explore

hotspot

SarahSilbiger/GettyImagesWASHINGTON—PanelsinboththeHouseandSenatehavenowpassedrestrictionstodrugmidd

WSS

Astellas still sees hope in its gene therapy after four deaths

NYU radiologists take on the challenge of expensive MRI machines

Wegovy, Zepbound and weight loss drugs that preserve muscle

Boston Scientific acquires urology company Axonics for $3.7 billion

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

A preacher's new calling: Diversifying neuroscience research

Wikipedia

explore

explore

New air purifier tech could be key to improving indoor air quality

CRISPR pioneers react to Casgevy, first gene

Hepatitis C has a cure — but many Americans still lack access to it

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Novavax promises a turnaround & Lilly roils the obesity market

In key trial, Verve's treatment lowers cholesterol levels in patients

Activists slam private health insurers over coverage restrictions

Morphosys mixed study results for blood cancer drug

Bright Health sells Medicare Advantage business to Molina

Study suggests new cause of Down syndrome: cells linked to aging

focus

STAT Virtual Event: JPM Recap, Live!

CRISPR pioneers react to Casgevy, first gene

David Sabatini, ex

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Weight loss drug costs may need more research, senator suggests

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

explore

hotspot

explore

hotspot